APA (7th ed.) Citation

J, M., A, R., A, I., JM, D., T, W., G, Z., . . . YH, K. (2026). Epcoritamab Plus Gemcitabine and Oxaliplatin Versus Rituximab Plus Gemcitabine and Oxaliplatin in Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Match-Adjusted Comparative Analysis. Clinical lymphoma, myeloma & leukemia, 26(2), e283. https://doi.org/10.1016/j.clml.2025.10.010

Chicago Style (17th ed.) Citation

J, Munoz, et al. "Epcoritamab Plus Gemcitabine and Oxaliplatin Versus Rituximab Plus Gemcitabine and Oxaliplatin in Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Match-Adjusted Comparative Analysis." Clinical Lymphoma, Myeloma & Leukemia 26, no. 2 (2026): e283. https://doi.org/10.1016/j.clml.2025.10.010.

MLA (9th ed.) Citation

J, Munoz, et al. "Epcoritamab Plus Gemcitabine and Oxaliplatin Versus Rituximab Plus Gemcitabine and Oxaliplatin in Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Match-Adjusted Comparative Analysis." Clinical Lymphoma, Myeloma & Leukemia, vol. 26, no. 2, 2026, p. e283, https://doi.org/10.1016/j.clml.2025.10.010.